Therefore, it is necessary to combine anti-PD-1/PD-L1 inhibitors with conventional treatments, including chemotherapy, radiation and targeted therapy to reduce the resistance and improve the anti-tumor effect (Figure 6). The gene discussed is CD274; the disease is neoplasm.